On Wednesday, Viatris Inc. (NASDAQ:VTRS) said it has inked a pact with Idorsia for a significant global research and development collaboration.
This partnership involves selatogrel, an innovative self-administered treatment for individuals with a background of acute myocardial infarction (AMI), also known as a heart attack.
Under the deal, Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets and additional innovative assets in the future.
It leverages Viatris’ worldwide cardiovascular portfolio, along with its distribution prowess in self-administered therapies for critical acute conditions.
The partnership additionally encompasses …
Leave a Reply